{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T05:18:05Z","timestamp":1692508685137},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00105-020-04555-w","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T14:03:02Z","timestamp":1583330582000},"page":"227-243","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapie der Psoriasis vulgaris im Erwachsenenalter"],"prefix":"10.1007","volume":"71","author":[{"given":"S.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Schultes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wilsmann-Theis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"4555_CR1","volume-title":"S3 \u2013 Leitlinie zur Therapie der Psoriasis vulgaris. Update 2017","author":"A Nast","year":"2017","unstructured":"Nast\u00a0A, Amelunxen\u00a0L, Augustin\u00a0M et\u00a0al (2017) S3 \u2013 Leitlinie zur Therapie der Psoriasis vulgaris. Update 2017"},{"key":"4555_CR2","volume-title":"Aktualisierter praxisnaher Behandlungspfad. Empfehlungen f\u00fcr die ambulante Versorgung von Psoriasis vulgaris","author":"R Kiedrowski","year":"2019","unstructured":"Kiedrowski\u00a0R, Dirschka\u00a0T, Kr\u00e4hn-Senftleben\u00a0G et al (2019) Aktualisierter praxisnaher Behandlungspfad. Empfehlungen f\u00fcr die ambulante Versorgung von Psoriasis vulgaris"},{"issue":"4","key":"4555_CR3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets\u00a0CA, Leonardi\u00a0CL, Davis\u00a0DMR et al (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J\u00a0Am Acad Dermatol 80(4):1073\u20131113","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4555_CR4","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/jdv.14861","volume":"32","author":"E Audureau","year":"2018","unstructured":"Audureau\u00a0E, Roux\u00a0F, Lons Danic\u00a0D (2018) Psoriatic arthritis screening by the dermatologist: development and first validation of the \u2018PURE\u20114 scale. J\u00a0Eur Acad Dermatol Venereol 32(11):1950\u20131953","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"4555_CR5","first-page":"46","volume":"12","author":"D Mikhaylov","year":"2019","unstructured":"Mikhaylov\u00a0D, Hashim\u00a0PW, Nektalova\u00a0T (2019) Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits. J\u00a0Clin Aesthet Dermatol 12(6):46\u201354","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"4555_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ddg.13810","volume":"17","author":"A K\u00f6rber","year":"2019","unstructured":"K\u00f6rber\u00a0A, Wilsmann-Theis\u00a0D, Augustin\u00a0M (2019) Topische Therapie bei\u00a0Psoriasis\u00a0vulgaris \u2013 ein Behandlungspfad. J\u00a0Dtsch Dermatol Ges 17(4):3\u20131","journal-title":"J Dtsch Dermatol Ges"},{"key":"4555_CR7","volume-title":"Topische Therapie der Psoriasis","author":"D Wilsmann-Theis","year":"2016","unstructured":"Wilsmann-Theis\u00a0D, Gerdes\u00a0S, K\u00f6rber\u00a0A et al (2016) Topische Therapie der Psoriasis, 1.\u00a0Aufl. UNI-MED, Bremen","edition":"1"},{"issue":"11","key":"4555_CR8","first-page":"1156","volume":"13","author":"C Painsi","year":"2015","unstructured":"Painsi\u00a0C, Patscheider\u00a0M, Inzinger\u00a0M et\u00a0al (2015) Patient perspectives on treating\u00a0psoriasis\u00a0with classic inpatient dithranol therapy: a\u00a0retrospective patient survey. J\u00a0Dtsch Dermatol Ges 13(11):1156\u20131163","journal-title":"J Dtsch Dermatol Ges"},{"key":"4555_CR9","unstructured":"PUREN Pharma GmbH & Co. KG (2019) Aktuelle Fachinformationen Acicutan Stand 08\/2019 bzw. Neotigason Stand 09\/2019"},{"issue":"6","key":"4555_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00105-016-3804-4","volume":"67","author":"P Weisenseel","year":"2016","unstructured":"Weisenseel\u00a0P, Wilsmann-Theis\u00a0D, Kahl\u00a0C et al (2016) Pustular psoriasis. Hautarzt 67(6):445\u2013453","journal-title":"Hautarzt"},{"issue":"1","key":"4555_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"B Shivani","year":"2019","unstructured":"Shivani\u00a0B, Kaushik\u00a0M, Lebwohl\u00a0M (2019) Psoriasis: which therapy for which patient focus on special populations and chronic infections. J\u00a0Am Acad Dermatol 80(1):43\u201353","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4555_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik\u00a0SB, Lebwohl\u00a0MG (2019) Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J\u00a0Am Acad Dermatol 80(1):27\u201340","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"4555_CR13","first-page":"856","volume":"17","author":"L Eisert","year":"2019","unstructured":"Eisert\u00a0L, Augustin\u00a0M, Bach\u00a0S et\u00a0al (2019) S2k guidelines for the treatment of psoriasis in children and adolescents\u2014Short version part 1. J\u00a0Dtsch Dermatol Ges 17(8):856\u2013870","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"4555_CR14","first-page":"821","volume":"10","author":"S Philipp","year":"2012","unstructured":"Philipp\u00a0S, Wilsmann-Theis\u00a0D, Weyergraf\u00a0A (2012) Combination of adalimumab with traditional systemic antipsoriatic drugs\u2014a\u00a0report of 39 cases. J\u00a0Dtsch Dermatol Ges 10(11):821\u2013837","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"4555_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s13555-019-0308-z","volume":"9","author":"XH Jin","year":"2019","unstructured":"Jin\u00a0XH, Chen\u00a0X, Mou\u00a0Y (2019) Effects of cyclosporine on palmoplantar pustulosis and serum expression of IL-17, IL-23, and TNF\u2011\u03b1. Dermatol Ther 9(3):547\u2013552","journal-title":"Dermatol Ther"},{"issue":"6","key":"4555_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00403-018-1825-9","volume":"310","author":"L Landeck","year":"2018","unstructured":"Landeck\u00a0L, Asadullah\u00a0K, Amasuno\u00a0A (2018) Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a\u00a0review of clinical data. Arch Dermatol Res 310(6):475\u2013483","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"4555_CR17","first-page":"180","volume":"15","author":"P Weisenseel","year":"2017","unstructured":"Weisenseel\u00a0P, Reich\u00a0K, Griemberg\u00a0W et al (2017) Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST). J\u00a0Dtsch Dermatol Ges 15(2):180\u2013186","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"4555_CR18","doi-asserted-by":"publisher","first-page":"e0221823","DOI":"10.1371\/journal.pone.0221823","volume":"14","author":"AM Bujor","year":"2019","unstructured":"Bujor\u00a0AM, Janjua\u00a0S, LaValley\u00a0MP (2019) Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS ONE 14(9):e221823","journal-title":"PLoS ONE"},{"key":"4555_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10067-016-3398-3","volume":"36","author":"AN Malaviya","year":"2017","unstructured":"Malaviya\u00a0AN et\u00a0al (2017) Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen. Clin Rheumatol 36:279\u2013285","journal-title":"Clin Rheumatol"},{"key":"4555_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18384","author":"K Reich","year":"2019","unstructured":"Reich\u00a0K, Augustin\u00a0M, Tha\u00e7i\u00a0D et al (2019) A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.18384","journal-title":"Br J Dermatol"},{"key":"4555_CR21","volume-title":"Fachinformation Metex","author":"Gelbe Liste Pharmindex","year":"2019","unstructured":"Gelbe Liste Pharmindex (2019) Fachinformation Metex"},{"issue":"4","key":"4555_CR22","first-page":"757","volume":"53","author":"C Weber-Schoendorfer","year":"2014","unstructured":"Weber-Schoendorfer\u00a0C, Hoeltzenbein\u00a0M, Wacker\u00a0E (2014) No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Baillieres Clin Rheumatol 53(4):757\u2013763","journal-title":"Baillieres Clin Rheumatol"},{"issue":"6","key":"4555_CR23","first-page":"557","volume":"14","author":"S Volc","year":"2016","unstructured":"Volc\u00a0S, Ghoreschi\u00a0K (2016) Pathophysiological basis of systemic treatments in psoriasis. J\u00a0Dtsch Dermatol Ges 14(6):557\u2013572","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"4555_CR24","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/jdv.14454","volume":"31","author":"A Nast","year":"2017","unstructured":"Nast\u00a0A, Spuls\u00a0PI, van der Kraaij\u00a0G et al (2017) European S3-guideline on the systemic treatment of psoriasis vulgaris\u2014update apremilast and secukinumab\u2014EDF in cooperation with EADV and IPC. J\u00a0Eur Acad Dermatol Venereol 31(12):1951\u20131963","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"4555_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00105-019-4396-6","volume":"70","author":"A Pinter","year":"2019","unstructured":"Pinter\u00a0A, Beigel\u00a0F, K\u00f6rber\u00a0A et\u00a0al (2019) Gastrointestinale Beschwerden unter Apremilast: Charakterisierung und Management. Hautarzt 70(5):354\u2013362","journal-title":"Hautarzt"},{"key":"4555_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.018","author":"SE Mazloom","year":"2018","unstructured":"Mazloom\u00a0SE, Yan\u00a0D, Hu\u00a0JZ et al (2018) TNF\u2011\u03b1 inhibitor-induced psoriasis: a decade of experience at the cleveland clinic. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2018.12.018","journal-title":"J Am Acad Dermatol"},{"key":"4555_CR27","unstructured":"Rote Liste Service GmbH (2019) Fachinformation Ixekizumab Stand 07\/2019"},{"issue":"2","key":"4555_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.15277","volume":"33","author":"LM Sawyer","year":"2019","unstructured":"Sawyer\u00a0LM, Cornic\u00a0L, Levin\u00a0L\u00c5, Gibbons\u00a0C, M\u00f8ller\u00a0AH, Jemec\u00a0GB (2019) Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a\u00a0systematic review and network meta-analysis of PASI response. J\u00a0Eur Acad Dermatol Venereol 33(2):355\u2013366","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"4555_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/1346-8138.14318","volume":"45","author":"D Wilsmann-Theis","year":"2018","unstructured":"Wilsmann-Theis\u00a0D, Schnell\u00a0LM, Ralser-Isselstein\u00a0V et al (2018) Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J\u00a0Dermatol 45(7):850\u2013854","journal-title":"J Dermatol"},{"issue":"6","key":"4555_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","volume":"29","author":"J Bilal","year":"2018","unstructured":"Bilal\u00a0J, Berlinberg\u00a0A, Bhattacharjee\u00a0S, Trost\u00a0J, Riaz\u00a0IB, Kurtzman\u00a0DJB (2018) A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J\u00a0Dermatolog Treat 29(6):569\u2013578","journal-title":"J Dermatolog Treat"},{"issue":"10198","key":"4555_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich\u00a0K, Gooderham\u00a0M, Tha\u00e7i\u00a0D et al (2019) Risankizumab\u00a0compared with\u00a0adalimumab\u00a0in patients with moderate-to-severe plaque psoriasis (IMMvent): a\u00a0randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 394(10198):576\u2013586","journal-title":"Lancet"},{"issue":"4","key":"4555_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi\u00a0YA, Dey\u00a0AK, Goyal\u00a0A et\u00a0al (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a\u00a0prospective observational study. Cardiovasc Res 115(4):721\u2013728","journal-title":"Cardiovasc Res"},{"issue":"5","key":"4555_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","volume":"311","author":"I Gasslitter","year":"2019","unstructured":"Gasslitter\u00a0I, Kirsten\u00a0N, Augustin\u00a0M et al (2019) Successful intra-class switching among IL-17 antagonists: a\u00a0multicentre, multinational, retrospective study. Arch Dermatol Res 311(5):421\u2013424","journal-title":"Arch Dermatol Res"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04555-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-020-04555-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04555-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:24:02Z","timestamp":1614817442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-020-04555-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4555"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04555-w","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"4 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>D.\u00a0Wilsmann-Theis:<\/b> A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Forward Pharma, GlaxoSmithKline, Hexal, Janssen-Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer, UCB Pharma, VBL. \u2013 Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Forward Pharma, GlaxoSmithKline, Hexal, Janssen-Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer, UCB Pharma, VBL. \u2013 Beratung bez\u00fcglich der Wirksamkeit der einzelnen Produkte: AbbVie, Almirall, Biogen, Celgene, Fresenius-Kabi, GlaxoSmithKline, Hexal, Janssen-Cilag, Leo, Lilly, Medac, Novartis, Pfizer, UCB Pharma, VBL. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Dermatologin an der Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie des Universit\u00e4tsklinikum Bonn | Ober\u00e4rztin der Psoriasis-Spezialsprechstunde | Mitgliedschaft: Wissenschaftlicher Beirat des Deutschen Psoriasisbundes, Vorstandsmitglied des Psonets Bonn Rhein\/Sieg. <b>S.\u00a0M\u00fcller:<\/b> A.\u00a0Finanzielle Interessen: S.\u00a0M\u00fcller gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin der Dermatologie, Universit\u00e4tsklinikum Bonn. <b>D.\u00a0Schultes:<\/b> A.\u00a0Finanzielle Interessen: D.\u00a0Schultes gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Assistenzarzt an der Klinik f\u00fcr Dermatologie, Uniklinik Bonn.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}